Viloxazine

• Attention-deficit/hyperactivity disorder (ADHD) in patients 6 years and older
• Non-stimulant ADHD treatment option
• ADHD in patients with substance abuse history
• ADHD with comorbid anxiety or tic disorders
• Alternative when stimulants are not tolerated

Viloxazine, marketed as Qelbree, is a non-stimulant medication approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) in patients aged six years and older. Originally developed in the 1970s as an antidepressant in Europe (where it was known as Vivalan), the drug was reformulated as an extended-release product and reintroduced in the United States in 2021 specifically for ADHD. For families weighing the trade-offs between stimulant and non-stimulant treatment — and for adults with substance use history, comorbid anxiety, or strong personal preference against controlled medications — viloxazine has expanded what was previously a narrow non-stimulant menu (atomoxetine and the alpha-2 agonists guanfacine and clonidine).

Mechanism of Action

Viloxazine is a selective norepinephrine reuptake inhibitor with additional serotonergic activity. It blocks the norepinephrine transporter (NET), increasing synaptic norepinephrine concentrations in prefrontal cortex and other regions implicated in attention, executive function, and working memory. This norepinephrine-amplifying effect is the primary driver of its ADHD efficacy. Unlike atomoxetine — which has only NET inhibition — viloxazine also acts as a 5-HT2C receptor antagonist and a 5-HT2B receptor agonist, and it weakly inhibits serotonin reuptake. The serotonergic effects are thought to contribute to mood and anxiety modulation, although their precise contribution to ADHD efficacy is uncertain.

Fundamentally, viloxazine differs from stimulants in that it does not promote dopamine release in mesolimbic reward pathways — which is why it is not a controlled substance and lacks the abuse and diversion concerns associated with methylphenidate and amphetamine derivatives. The norepinephrine effect builds gradually rather than producing the rapid onset and offset of stimulant action, and clinical response typically requires one to two weeks for initial benefit and several weeks for full effect. Viloxazine is metabolized primarily by CYP2B6 and is itself a moderate inhibitor of CYP1A2, a property with significant implications for drug interactions. For broader background, our psychiatric specialty page and our cognitive health aging guide cover the spectrum of attention and cognitive treatments across the lifespan.

Clinical Use

Viloxazine is FDA-approved for ADHD in patients aged six and older. Pivotal pediatric trials demonstrated significant improvements in ADHD-RS-5 total scores compared with placebo across school-age and adolescent populations. The adult approval, granted in 2022, was based on a multicenter trial showing similar efficacy in adults. Within current ADHD guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians, stimulants remain first-line pharmacologic therapy because of larger effect sizes; non-stimulants are recommended when stimulants are contraindicated, ineffective, or not tolerated, or when patient preference favors a non-controlled option. Common scenarios for choosing viloxazine include comorbid anxiety (where stimulants may worsen symptoms), tic disorders, substance use history in the patient or household, severe stimulant-induced appetite suppression or insomnia, or simply patient and family preference. Compared with atomoxetine, viloxazine has a faster onset of meaningful effect (often visible within two weeks rather than four to eight) and may have somewhat fewer gastrointestinal side effects, though head-to-head data are limited. Behavioral therapy, parent training, and school-based supports remain critical components of comprehensive ADHD care.

How to Take It

Viloxazine is supplied as extended-release capsules in 100, 150, and 200 mg strengths. For children aged 6 to 11, the starting dose is 100 mg once daily, with weekly increases of 100 mg as tolerated to a target of 200 to 400 mg per day. For adolescents aged 12 to 17, the starting dose is 200 mg once daily, with weekly increases of 100 mg as tolerated to a maximum of 400 mg per day. Adults start at 200 mg once daily and titrate to a target of 200 to 600 mg per day. The medication is taken once daily, in the morning, with or without food. Capsules can be swallowed whole or, for patients who have difficulty swallowing, opened and the contents sprinkled on a teaspoon of pudding or applesauce — the mixture should be consumed within two hours and not stored. Capsules should not be chewed or crushed. If a dose is missed and remembered the same morning, it can be taken; if not until later in the day, it should be skipped to avoid insomnia. Effects build gradually: initial improvement often emerges within one to two weeks, with maximal benefit at four to six weeks. Common early experiences include sleepiness (which often improves), reduced appetite, mild nausea, and headache. Storage is room temperature.

Monitoring and Follow-Up

Before starting, baseline vital signs (heart rate, blood pressure), weight and height (for children), screening for cardiovascular family history, and screening for depression and suicidality are appropriate. ADHD symptom severity should be quantified at baseline using validated rating scales (such as the Vanderbilt or ADHD-RS-5) for tracking response. After initiation, follow-up at two weeks, six weeks, and three months allows assessment of efficacy, side effects, and dose adjustment. Heart rate and blood pressure should be checked at each follow-up — viloxazine can produce modest increases. For pediatric patients, weight and height should be tracked at every visit because some children experience appetite reduction and growth deceleration; documenting growth curves is essential. Suicidality screening should be specifically asked at each visit, given the boxed warning. Liver function tests are reasonable at baseline and if symptoms suggest hepatotoxicity. Mood, sleep, and school or work performance should be reviewed regularly. Reviewing your annual physical provides a structured opportunity for ongoing monitoring.

Special Populations

In elderly patients, no specific dose adjustment is established, but cardiovascular comorbidities and concomitant medications warrant cautious starting doses. In severe renal impairment (eGFR less than 30 mL/min/1.73 m2), the maximum dose for adults is 200 mg per day; the medication is not recommended in end-stage renal disease. Hepatic impairment data are limited and viloxazine should be used with caution in moderate to severe disease. Pregnancy data are limited; the drug should be used during pregnancy only if benefits clearly outweigh risks, with awareness that withdrawal symptoms may occur in newborns exposed in late pregnancy. Lactation data are absent — exposure through milk is theoretically possible. Pediatric safety has been established down to age six. Patients with bipolar disorder may experience activation or mood destabilization and require psychiatric coordination. Concomitant use with monoamine oxidase inhibitors is contraindicated due to risk of serious hypertensive and serotonergic reactions; a 14-day washout is required between MAOI and viloxazine. Because viloxazine moderately inhibits CYP1A2, doses of sensitive substrates such as duloxetine, tizanidine, theophylline, alosetron, and ramelteon may need adjustment.

When to Contact Your Doctor

Seek immediate care for any new or worsening thoughts of self-harm, severe agitation, mania, or psychosis — viloxazine carries a boxed warning for suicidal ideation in pediatric and young adult patients, and close monitoring is essential, especially during the first few months and after dose changes. Significantly elevated blood pressure or heart rate, chest pain, palpitations, or fainting warrant prompt evaluation. Persistent severe drowsiness interfering with school or driving, marked appetite loss with weight loss, or growth concerns in children should be discussed at the next visit. Severe nausea, abdominal pain, jaundice, or dark urine may suggest hepatotoxicity. Allergic reactions including rash, hives, facial swelling, or difficulty breathing require urgent attention. The MedlinePlus viloxazine page and the NIMH ADHD resource provide additional patient and family resources.

Practical Tips for Daily Use

Viloxazine is most effective when paired with structured behavioral and environmental supports. Take the dose at the same time each morning, ideally before school or work begins. If you switch from a stimulant to viloxazine, plan for a ramp-up period of two to six weeks during which symptom control may be incomplete; coordinate with school staff or supervisors to allow for accommodations during this transition. Maintain consistent sleep — irregular sleep dramatically worsens ADHD symptoms regardless of medication. Limit screens in the hour before bed, since the medication's modest activating effect plus blue-light exposure can compound insomnia. If appetite suppression occurs, front-load nutrition into breakfast (when the medication has not yet peaked) and provide nutrient-dense snacks rather than large dinners. For pediatric patients, plot height and weight at each visit so the family can see whether trajectories are on track. Regular aerobic exercise improves attention and mood in ADHD and complements pharmacotherapy. Behavioral therapy, executive function coaching, and parent training (for younger children) provide the scaffolding without which medication alone often falls short. If you take other medications metabolized through CYP1A2 — duloxetine, theophylline, tizanidine, ramelteon — review the regimen with your pharmacist when starting viloxazine, as dose adjustments may be needed.

Working With Your Care Team

ADHD treatment works best when medication is paired with behavioral strategies, school or workplace accommodations, and attention to sleep, exercise, and comorbid mental health. Schedule a visit with our team to discuss whether viloxazine fits your or your child's treatment plan, and to coordinate the broader supports that turn good medication response into lasting improvement.